Insmed (INSM) said Wednesday that brensocatib, its investigational dipeptidyl peptidase-1 inhibitor for non-cystic fibrosis bronchiectasis, demonstrated consistent efficacy and safety across three prespecified subgroups in the phase 3 Aspen trial.
The subgroup analyses included adolescents, patients on macrolide therapy, and those with varying blood eosinophil levels.
The data showed brensocatib reduced pulmonary exacerbations, prolonged time to first exacerbation, and slowed lung function decline compared with placebo, with a safety profile consistent with the overall trial population, according to the company.
The results were presented at the American Thoracic Society 2025 International Conference held between May 18 and May 21 in San Francisco.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.